Barclays Maintains an 'Overweight' on Teva Pharma (TEVA); P&G Partnership Has Multiple Benefits
Tweet Send to a Friend
Barclays maintains an 'Overweight' on Teva Pharma (NASDAQ: TEVA), PT $70.
Barclays analyst says, "Attractive and consistent with Teva's growth ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "Attractive and consistent with Teva's growth ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
